Related Experiment Video
Updated: Jun 16, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST
Mareike Verbeek1, Falko Fend, Thomas Licht
1III Medical Department, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, 81675 München, Germany.
Background:
A 71-year-old male patient was diagnosed as having a KIT-positive gastrointestinal stromal tumor located at the gastric antrum. With no signs of distant metastasis, the patient primarily underwent gastric surgery with antrectomy and Billroth-I-reconstruction. Owing to tumor size and mitotic index, the patient was considered at high risk of tumor relapse and thus was entered into a clinical trial to receive adjuvant imatinib treatment. 4 months after initiation of imatinib treatment, the patient presented with several newly discovered subcutaneous and intra-abdominal tumor lesions. Imatinib treatment had been tolerated well until then.
Investigations:
Physical examination, blood tests, biopsies of the subcutaneous tumor lesions, tumor morphology and immunohistochemistry, PCR for the T-cell receptor gamma genes, sequential CT and PET-CT.
Diagnosis:
Monoclonal T-cell lymphoproliferative disorder, potentially induced by imatinib.
Management:
Imatinib was stopped, after which the tumor lesions spontaneously regressed and, eventually, complete remission was achieved.
More Related Videos
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018